Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201
Targeted treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is the current standard of care for EGFR-mutated advanced/metastatic non-small cell lung cancer (NSCLC), which typically exhibits a five-year survival rate of 25 –30 % [1,2]. Notably, in Asia, nearly half of the patients diagnosed with lung adenocarcinoma harbor classical activating EGFR mutations (exon 19 deletions [Ex19Del] and L858R point mutation in exon 21 [3]. Patients with these mutations were found to exhibit favorable clinical responses to first -generation EGFR TKIs [4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Byoung Chul Cho, Ji-Youn Han, Ki Hyeong Lee, Yun-Gyoo Lee, Dong-Wan Kim, Young Joo Min, Sang-We Kim, Eun Kyung Cho, Joo-Hang Kim, Gyeong-Won Lee, Sung Sook Lee, NaMi Lee, Jang Young Wang, Hyejoo Park, Myung-Ju Ahn Source Type: research